Entropy Neurodynamics Limited (ASX: ENP), a clinical-stage biotechnology company developing proprietary psilocin-based therapies, has secured a South African patent covering methods of treating fibromyalgia using psilocybin. The patent grant, issued under South African Patent No. 2025/01722, extends intellectual property protection until September 2043 and encompasses treatment methods, dosing regimens, patient selection criteria, clinical protocols and manufacturing processes. The development strengthens the company’s global patent portfolio as it advances its psychedelic medicine platform, with the fibromyalgia treatment market in South Africa valued at US$1.9 billion in 2025.
Key Points
- Entropy Neurodynamics Limited (ASX: ENP) is a clinical-stage biotechnology company focused on developing novel psilocin formulations for treating diseases with significant unmet medical needs
- South African patent granted covering methods of treating fibromyalgia using psilocybin and psilocin-based treatments, providing broad intellectual property protection
- Patent protection extends to 11 September 2043 and encompasses treatment methods, dosing regimens, patient selection, clinical assessment protocols, biomarkers, outcome measures and manufacturing
- The South African fibromyalgia treatment market was valued at US$1.9 billion in 2025, presenting a significant commercial opportunity for the company’s therapeutic platform
- Patent claims are designed to be difficult for competitors to replicate, creating comprehensive indication-level intellectual property protection beyond simple psilocybin use
- The grant complements Entropy’s broader IP strategy focused on securing protection across key therapeutic indications and jurisdictions globally
Comprehensive Patent Coverage Extends Beyond Simple Psilocybin Use
The South African patent granted to Entropy Neurodynamics provides substantially broader protection than typical pharmaceutical patents covering a single active ingredient. Rather than simply protecting the use of psilocybin for fibromyalgia treatment, the patent encompasses a comprehensive therapeutic framework designed to establish meaningful commercial exclusivity. The patent claims cover therapeutic methods, dosing regimens, patient selection criteria, clinical assessment protocols, biomarkers, treatment outcome measures, integration therapy and manufacture, creating what the company describes as indication-level intellectual property protection.
This strategic breadth in patent claims reflects a sophisticated approach to IP development in the emerging psychedelic medicine sector. By protecting not only the compound and its use but also the treatment methodology, dosing protocols, patient selection approaches and clinical assessment frameworks, Entropy has constructed protective barriers that extend well beyond what competitors could circumvent through minor formulation or dosing adjustments. The company stated that these claims have been devised to be difficult for competitors to design around, potentially providing significant competitive advantages as psychedelic-assisted therapies move through clinical development and toward commercialisation. This comprehensive approach to patent protection aligns with best practices in biotech IP strategy where protection extends across the entire therapeutic ecosystem rather than narrowly protecting individual elements.
Fibromyalgia Market Opportunity and Unmet Medical Need
Fibromyalgia represents a substantial global market opportunity and a disease area with significant unmet medical need. The condition is characterised by widespread musculoskeletal pain, fatigue, sleep disturbance and cognitive impairment, affecting millions of people worldwide. Currently available therapies provide limited efficacy for many patients, leaving a substantial proportion of the fibromyalgia population without adequate treatment options. This therapeutic gap creates a compelling clinical and commercial opportunity for novel treatment approaches, particularly those addressing multiple symptom domains simultaneously.
The South African fibromyalgia treatment market alone was valued at US$1.9 billion in 2025, according to the company update. This substantial market size in a single jurisdiction underscores the commercial potential for effective fibromyalgia therapies globally. The market valuation suggests significant demand for improved treatment options and positions Entropy’s psilocybin and psilocin-based approaches as potentially valuable additions to the fibromyalgia treatment landscape. As psychedelic-assisted therapies continue to gain clinical acceptance and regulatory approval, markets like South Africa represent important territorial opportunities for companies holding relevant patent protection. The combination of unmet medical need and substantial market size makes fibromyalgia an attractive indication for Entropy’s development pipeline.
Entropy’s Lead Program TRP-8803 and Proprietary IV-Infused Psilocin Platform
Entropy Neurodynamics’ lead therapeutic program is TRP-8803, a proprietary formulation of intravenously infused psilocin—the active metabolite of psilocybin—designed for administration in combination with psychotherapy. This formulation approach addresses multiple shortcomings associated with oral psilocybin administration, including significantly reducing the time to onset of the psychedelic state, controlling the depth and duration of the psychedelic experience, and reducing the overall duration of the intervention to a commercially feasible timeframe. The development of a controlled-delivery IV formulation represents a significant advancement over traditional oral psilocybin approaches, potentially enabling faster therapeutic onset and more predictable treatment duration.
The development pathway for TRP-8803 has been informed by Phase 2a clinical trials using oral psilocybin for the treatment of Binge Eating Disorder, Irritable Bowel Syndrome and Fibromyalgia. Results from these trials demonstrated the clinical benefits of psychedelic therapy and have provided the clinical evidence base to guide further development of the IV-infused formulation. This systematic progression from oral psilocybin clinical trials to a proprietary IV formulation reflects a staged development approach designed to refine and optimise the therapeutic benefits of psilocin-based therapy. The breadth of indications under investigation—spanning psychiatric, gastrointestinal and pain disorders—suggests a broad therapeutic platform approach rather than development narrowly focused on a single indication.
Global IP Strategy and Long-Term Commercial Exclusivity Until 2043
The South African patent grant represents a deliberate expansion of Entropy’s global intellectual property estate, which the company has identified as a key strategic priority. The company’s IP strategy is focused on securing protection across key therapeutic indications and jurisdictions to maximise the long-term commercial value of its psychedelic medicine platform. This multi-jurisdictional, multi-indication approach to patent protection reflects recognition that global commercialisation of novel therapeutics requires robust territorial IP coverage to support manufacturing partnerships, licensing arrangements and direct market entry in key jurisdictions.
The South African patent protection extends to 11 September 2043, subject to payment of annual renewal fees, providing approximately 17 years of exclusivity from the date of the company update in July 2026. This patent term provides a substantial commercial exclusivity window supporting Entropy’s long-term commercialisation strategy and future partnering opportunities. Patents extending to 2043 offer sufficient protection period to support clinical development, regulatory approval, market launch and significant commercial exploitation of successful therapies. The maintenance of this patent term depends on timely payment of annual renewal fees, a standard administrative requirement for patent protection in South Africa and most other jurisdictions. The long patent tail to 2043 provides meaningful incentive for development investment and supports potential licensing or partnership discussions with larger pharmaceutical companies seeking long-term territorial rights.
CEO Commentary on IP Strategy and Competitive Positioning
Entropy Neurodynamics CEO Jason Carroll provided commentary on the strategic significance of the South African fibromyalgia patent, describing it as an important addition to the company’s growing intellectual property portfolio that significantly strengthens its position in fibromyalgia treatment. Carroll emphasised that the breadth of the patent claims extends well beyond simple protection of psilocybin use, encompassing the broader therapeutic framework including dosing protocols, patient selection, clinical assessments and treatment methodology. This comprehensive, indication-level intellectual property protection, according to management commentary, is designed to be difficult for competitors to replicate, providing competitive advantage as the company advances its clinical development programs.
Carroll further noted that building a robust global patent estate remains a key strategic priority as Entropy continues to generate clinical evidence across its precision-controlled psychedelic platform. The CEO stated that strong intellectual property enhances the long-term value of development programs, supports future partnering opportunities and reinforces commercial positioning as the company seeks to develop next-generation psychedelic therapies for patients with significant unmet medical needs. This statement reflects management’s view that IP protection is not merely a defensive mechanism but a central pillar of commercial strategy supporting partnering, licensing and market development activities. The emphasis on building a “robust global patent estate” suggests the company anticipates pursuing additional patent protection across multiple jurisdictions and therapeutic indications beyond fibromyalgia.
Psychedelic Medicine Development Program Scope and Clinical Evidence
Entropy Neurodynamics operates across a platform approach to psychedelic medicine development spanning multiple therapeutic indications. Beyond fibromyalgia, the company has conducted Phase 2a clinical trials using oral psilocybin for the treatment of Binge Eating Disorder and Irritable Bowel Syndrome. This breadth of indication development reflects a strategic approach to maximising the commercial potential of the psilocybin and psilocin platform by addressing multiple disease areas with significant unmet medical needs. The development across psychiatric, gastrointestinal and pain disorders suggests that Entropy views psychedelic-assisted therapy as a broadly applicable treatment modality rather than one limited to a single therapeutic category.
The clinical evidence generated from Phase 2a trials with oral psilocybin has been used to inform and enhance the development of TRP-8803, the company’s proprietary IV-infused psilocin formulation. This iterative development approach—leveraging clinical data from earlier-stage trials to guide later-stage formulation development—reflects a systematic methodology for advancing psychedelic therapeutics. The multiple therapeutic indications under investigation provide several potential near-term milestone opportunities as the company progresses development of its IV-infused platform. The breadth of the clinical trial program also provides substantial data supporting patent claims across multiple therapeutic categories, potentially strengthening the company’s overall patent portfolio and supporting the indication-level IP protection strategy.
Regulatory Environment and Risk Considerations in Psychedelic Medicine Development
Development of psilocybin and psilocin-based therapies operates within a complex and evolving regulatory environment. While several jurisdictions have implemented clinical trial exemptions or accelerated pathways for psychedelic therapeutics, regulatory status remains subject to change. The company update includes a risk disclosure noting that all medicines carry risks and that specialist prescribers, such as registered psychiatrists, are best placed to assess the suitability of new medications against individual patient circumstances and medical history. Adverse effects of psilocybin and related compounds such as psilocin can include temporary increases in blood pressure and raised heart rate, with potential risk of psychosis in predisposed individuals, though the company notes these effects are unlikely at low doses and in treatment regimens used in psychedelic-assisted psychotherapy with appropriate medical supervision.
The regulatory pathway for psychedelic medicines remains uncertain in many jurisdictions, and approval timelines may extend significantly beyond those typical for conventional pharmaceuticals. Regulatory bodies in different countries maintain different frameworks for psilocybin and psilocin-based therapies, potentially complicating global development and commercialisation strategies. The South African patent protection, while valuable, depends on regulatory environments in South Africa and other key markets developing in ways that permit clinical development and commercialisation of psilocin-based therapies. Changes in regulatory classification, scheduling or approval pathways in major markets could materially affect the commercial value of Entropy’s IP portfolio and development programs. These regulatory uncertainties represent a significant development risk specific to the psychedelic medicine sector and should be carefully considered by investors evaluating the company’s long-term commercial prospects.
Competitive Positioning and Patent Design-Around Resistance
The company has positioned the South African fibromyalgia patent claims as intentionally difficult for competitors to design around, suggesting management’s assessment that the patent provides meaningful competitive moat beyond simple product protection. By securing claims covering not only the use of psilocybin and psilocin but also therapeutic methodology, dosing protocols, patient selection frameworks and clinical assessment approaches, Entropy has created barriers that extend across the entire treatment ecosystem. A competitor seeking to develop alternative fibromyalgia therapies would face challenges in operating around claims spanning multiple elements of the therapeutic framework rather than merely the active ingredient.
However, patent design-around is possible across a multi-claim patent estate, and competitors could potentially develop alternative psilocin formulations, delivery methods or treatment protocols not specifically covered by the South African patent. The effectiveness of the patent in preventing competitive entry also depends on factors beyond patent scope, including the breadth of claims that ultimately survive patent examination in other key jurisdictions, the company’s ability and willingness to enforce patents against infringers, and the emergence of alternative therapeutic approaches to fibromyalgia treatment. Patents provide powerful but not absolute competitive advantages, and their effectiveness varies significantly depending on technical scope, territorial coverage and enforcement feasibility. Investors should consider the South African patent as one important element of Entropy’s competitive positioning rather than a guarantee of long-term market exclusivity.
Next Development Milestones and Strategic Outlook
While the company update does not provide explicit guidance on next clinical or regulatory milestones, the South African patent grant signals ongoing progress in the company’s IP development strategy. The company has indicated that building a robust global patent estate remains a key strategic priority, suggesting investors should anticipate additional patent grants and applications across multiple jurisdictions and therapeutic indications. The progression of TRP-8803 through clinical development and the potential advancement toward regulatory submission in key markets represent important future milestones that investors may be watching. The combination of ongoing clinical development, patent portfolio expansion and potential partnerships with larger pharmaceutical companies represents the near-term strategic trajectory suggested by the company’s public commentary.
Entropy’s stated focus on “future partnering opportunities” suggests the company may be positioning for licensing arrangements or strategic collaborations with larger pharmaceutical companies seeking access to psychedelic medicine intellectual property and clinical programs. Such partnerships could provide near-term value realisation and capital for continued development while maintaining equity ownership and upside participation. The long patent term extending to 2043 provides a substantial territorial rights package that could support attractive partnership economics for prospective partners. Investors should monitor announcements regarding clinical trial progression, regulatory submissions, geographic patent grants, and any strategic partnership discussions as the company executes its global development and commercialisation strategy.
